Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Bausch Health Companies Inc NYSE: BHC-N

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 27.52
Day High 28.23
Open:28.08
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, is based in NJ, United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Bausch Health Companies Inc. Announces First-Quarter 2021 Results
- PR Newswire - PRF - Tue May 4, 5:59AM CDT
PR Newswire - PRF - CMTX
Tue May 4, 5:59AM CDT
, /PRNewswire/ -- 
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
- PR Newswire - PRF - Mon May 3, 6:00AM CDT
PR Newswire - PRF - CMTX
Mon May 3, 6:00AM CDT
, /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by through the redemption of outstanding senior secured notes, using cash generated from operations.
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
- PR Newswire - PRF - Thu Apr 29, 5:59AM CDT
PR Newswire - PRF - CMTX
Thu Apr 29, 5:59AM CDT
LAVAL, QC, /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of new scientific data and clinical analyses, including one podium presentation and 11 poster presentations, during the virtual Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place from . The virtual presentations will feature several of the company's prominent products from its pharmaceutical, surgical and vision care portfolios, as well as data from the company's ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. Analyses on the company's investigational drug XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) will also be highlighted."The new data and analyses we are presenting at ARVO this year represent our ongoing commitment to research and development across our business and to providing practitioners with new information that can help inform the treatment and care of their patients," said , U.S. president, Bausch + Lomb. "Among the data to be featured are insights from our ARMOR surveillance study, which continues to be the only ongoing multicenter study in that monitors in vitro antibiotic resistance among ocular pathogens, and  data on XIPERE™. We are proud to support these important studies and share the latest findings with eye care professionals during the ARVO meeting."  
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 27.52 +1.83% increase
on 05/05/21
Period Open:31.52
Price movement based on the high, low and last over the given period.
34.50 -18.75% decrease
on 04/28/21
-3.49 (-11.07%) decrease
since 04/05/21
3-Month 27.52 +1.83% increase
on 05/05/21
Period Open:28.13
Price movement based on the high, low and last over the given period.
34.80 -19.45% decrease
on 03/09/21
-0.10 (-0.36%) decrease
since 02/05/21
52-Week 14.86 +88.63% increase
on 09/30/20
Period Open:16.78
Price movement based on the high, low and last over the given period.
34.80 -19.45% decrease
on 03/09/21
+11.25 (+67.04%) increase
since 05/05/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies